<DOC>
	<DOCNO>NCT02978599</DOCNO>
	<brief_summary>Single-center , outpatient , randomize , double-blind , placebo-controlled , 3-treatment-phase , cross-over study evaluate safety , tolerability efficacy two oral dos AVL-3288 compare placebo , patient schizophrenia .</brief_summary>
	<brief_title>Clinical Trial AVL-3288 Schizophrenia Patients</brief_title>
	<detailed_description>This study 24 non-smoking outpatient schizophrenia schizoaffective disorder . Subjects complete three treatment phase , involve 5 straight day take AVL-3288 ( 10 mg 30 mg study drug placebo ) follow 16 day washout period subject take study drug ensure drug complete eliminate body next phase .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>DSMV diagnosis schizophrenia schizoaffective disorder RBANS Total Scale Score &gt; 65 Willing provide inform consent Medically stable study participation Taking antipsychotic medication clozapine stable dose least 4 week Judged clinically significant suicide violence risk Substance abuse ( exclude nicotine ) within last 90 day ECG abnormality clinically significant Current clozapine use Participation study investigational medication/device within 4 week Pregnancy , lactation , lack use effective birth control Active tobacco use Presence positive history significant medical neurological illness , include cardiac illness , WBC &lt; 3500/mm3 , absolute neutrophil count &lt; 1500/mm3 , ALT AST value &gt; 1.5 time upper limit normal . Hemoglobin le 130 g/L ( 13 g/dL ) males 120 g/L ( 12 g/dL ) females know HIV + Contraindication MRI scanning , include metal implant claustrophobia Medicinal patch , unless remove</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>